Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 38


What happens after an elevated PSA test: the experience of 13,591 veterans.

Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW.

J Gen Intern Med. 2010 Nov;25(11):1205-10. doi: 10.1007/s11606-010-1468-9. Epub 2010 Aug 10.


NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT.

J Natl Compr Canc Netw. 2010 Feb;8(2):240-62. No abstract available.


Prostate specific antigen best practice statement: 2009 update.

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P.

J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.


Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H.

Eur Urol. 2009 Nov;56(5):753-60. doi: 10.1016/j.eururo.2009.07.047. Epub 2009 Aug 7.


Timely follow-up of positive fecal occult blood tests strategies associated with improvement.

Powell AA, Gravely AA, Ordin DL, Schlosser JE, Partin MR.

Am J Prev Med. 2009 Aug;37(2):87-93. doi: 10.1016/j.amepre.2009.05.013. Epub 2009 Jun 12.


Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.


Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.


Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL.

BJU Int. 2008 Dec;102(11):1524-30. doi: 10.1111/j.1464-410X.2008.08214.x.


Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization.

Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC.

Med Care. 2008 Sep;46(9 Suppl 1):S91-6. doi: 10.1097/MLR.0b013e31817946c8.


It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.

Thompson IM, Ankerst DP, Etzioni R, Wang T.

J Urol. 2008 Oct;180(4):1219-22. doi: 10.1016/j.juro.2008.07.089. Epub 2008 Aug 15. No abstract available.


Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.


Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.

J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.


Continuity of care and cancer screening among health plan enrollees.

Fenton JJ, Franks P, Reid RJ, Elmore JG, Baldwin LM.

Med Care. 2008 Jan;46(1):58-62.


Methods of calculating prostate-specific antigen velocity.

Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF.

Eur Urol. 2007 Oct;52(4):1044-50. Epub 2006 Dec 18.


Does PSA velocity predict prostate cancer in pre-screened populations?

Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH.

Eur Urol. 2006 Mar;49(3):460-5; discussion 465. Epub 2006 Jan 17.


Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.


Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr.

JAMA. 2005 Jul 6;294(1):66-70.


Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

Carroll PR.

J Urol. 2005 Apr;173(4):1061-2. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk